Leerink Partnrs Reduces Earnings Estimates for Genmab A/S

Key Points

• Leerink Partners has reduced its FY2026 earnings per share estimate for Genmab A/S from $1.99 to $1.12, indicating a significant downward adjustment.
• The company's recent quarterly earnings of $0.54 exceeded analysts' estimates of $0.39, demonstrating a strong performance despite lower revenue expectations.
• Genmab A/S currently holds a consensus rating of "Moderate Buy" with a price target averaging $40.80, following ratings upgrades from several analysts.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) - Leerink Partnrs cut their FY2026 EPS estimates for Genmab A/S in a research report issued on Sunday, October 12th. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings of $1.12 per share for the year, down from their prior estimate of $1.99. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.39 by $0.15. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The firm had revenue of $925.00 million during the quarter, compared to analysts' expectations of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS.

Several other equities analysts also recently commented on GMAB. Zacks Research upgraded shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, October 2nd. HC Wainwright increased their target price on shares of Genmab A/S from $36.00 to $40.00 and gave the stock a "buy" rating in a report on Thursday, October 2nd. Wall Street Zen upgraded shares of Genmab A/S from a "buy" rating to a "strong-buy" rating in a report on Friday, September 26th. Weiss Ratings reiterated a "hold (c)" rating on shares of Genmab A/S in a research note on Wednesday, October 8th. Finally, Truist Financial increased their target price on shares of Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $40.80.

Genmab A/S Stock Up 0.2%

Shares of GMAB stock opened at $32.75 on Wednesday. The company's fifty day simple moving average is $27.29 and its 200-day simple moving average is $23.07. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $33.63. The firm has a market cap of $21.03 billion, a PE ratio of 16.46, a P/E/G ratio of 1.84 and a beta of 0.98.

Institutional Investors Weigh In On Genmab A/S

Several large investors have recently bought and sold shares of GMAB. Aaron Wealth Advisors LLC bought a new stake in shares of Genmab A/S during the 3rd quarter valued at about $228,000. GAMMA Investing LLC increased its position in shares of Genmab A/S by 55.4% during the 3rd quarter. GAMMA Investing LLC now owns 2,982 shares of the company's stock valued at $91,000 after purchasing an additional 1,063 shares during the last quarter. Osaic Holdings Inc. grew its position in Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company's stock valued at $33,000 after acquiring an additional 440 shares during the last quarter. Squarepoint Ops LLC grew its position in shares of Genmab A/S by 636.3% during the 2nd quarter. Squarepoint Ops LLC now owns 94,233 shares of the company's stock worth $1,947,000 after buying an additional 81,434 shares in the last quarter. Finally, Evergreen Capital Management LLC purchased a new stake in shares of Genmab A/S during the 2nd quarter worth $200,000. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.